{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:04:24Z","timestamp":1784279064582,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100015086","name":"AOP Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-026-06147-x","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:16:49Z","timestamp":1784276209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BMI-dependent norepinephrine trajectories during vasopressin therapy in septic shock persist independent of weight-normalization and body composition"],"prefix":"10.1186","volume":"30","author":[{"given":"Max","family":"Melchers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-7192","authenticated-orcid":false,"given":"Arthur Raymond Hubert","family":"van Zanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"6147_CR1","doi-asserted-by":"crossref","unstructured":"Wendel-Garcia PD, Morales S, Melo P, Kiavialaitis GE, Wohlrab P, Castro R et al. Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness. Crit Care. 2026;30(1):176.","DOI":"10.1186\/s13054-026-05994-y"},{"issue":"4","key":"6147_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/CCM.0000000000007089","volume":"54","author":"HC Prescott","year":"2026","unstructured":"Prescott HC, Antonelli M, Alhazzani W, M\u00f8ller MH, Alshamsi F, Azevedo LCP, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725\u2013812.","journal-title":"Crit Care Med"},{"issue":"9","key":"6147_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J, Gordon AC, H\u00e9bert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877\u201387.","journal-title":"N Engl J Med"},{"issue":"1","key":"6147_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13613-022-01021-9","volume":"12","author":"MA Ammar","year":"2022","unstructured":"Ammar MA, Ammar AA, Wieruszewski PM, Bissell BD, Albert MTL. Timing of vasoactive agents and corticosteroid initiation in septic shock. Ann Intensive Care. 2022;12(1):47.","journal-title":"Ann Intensive Care"},{"issue":"4","key":"6147_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/SHK.0000000000001086","volume":"50","author":"H Torbic","year":"2018","unstructured":"Torbic H, Sacha GL, Bauer SR, Lam SW. Body Mass\u2019s Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. Shock. 2018;50(4):388\u201394.","journal-title":"Shock"},{"key":"6147_CR6","doi-asserted-by":"crossref","unstructured":"Melchers M, Pickkers P, van Zanten ARH. Attenuated hemodynamic response to adjunct vasopressin in obese septic shock patients: a physiological or dose-dependent effect? Crit Care. 2026;30(1):69.","DOI":"10.1186\/s13054-026-05871-8"},{"issue":"1","key":"6147_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4037\/ajcc2016667","volume":"25","author":"JJ Radosevich","year":"2016","unstructured":"Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine Dosing in Obese and Nonobese Patients With Septic Shock. Am J Crit Care. 2016;25(1):27\u201332.","journal-title":"Am J Crit Care"},{"key":"6147_CR8","doi-asserted-by":"publisher","first-page":"106617","DOI":"10.1016\/j.clnu.2026.106617","volume":"59","author":"MC Paulus","year":"2026","unstructured":"Paulus MC, Melchers M, Kouw IWK, van Zanten ARH. Challenges in bedside skeletal muscle mass assessment: Limitations of fluid overload correction in critical illness. Clin Nutr. 2026;59:106617.","journal-title":"Clin Nutr"},{"issue":"1","key":"6147_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13613-025-01472-w","volume":"15","author":"M Melchers","year":"2025","unstructured":"Melchers M, de Smet V, Rooijakkers C, Huising J, Vermeulen W, K\u00f6kta\u015f BNN, et al. Hemodynamic effects of adjunct arginine vasopressin to norepinephrine in septic shock: insights from a prospective multicenter registry study. Ann Intensive Care. 2025;15(1):59.","journal-title":"Ann Intensive Care"},{"issue":"5","key":"6147_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1592\/phco.28.5.591","volume":"28","author":"SW Lam","year":"2008","unstructured":"Lam SW, Bauer SR, Cha SS, Oyen LJ. Lack of an effect of body mass on the hemodynamic response to arginine vasopressin during septic shock. Pharmacotherapy. 2008;28(5):591\u20139.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"6147_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/1060028016656384","volume":"50","author":"EK Hodge","year":"2016","unstructured":"Hodge EK, Hughes DW, Attridge RL. Effect of Body Weight on Hemodynamic Response in Patients Receiving Fixed-Dose Vasopressin for Septic Shock. Ann Pharmacother. 2016;50(10):816\u201323.","journal-title":"Ann Pharmacother"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06147-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:16:52Z","timestamp":1784276212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-06147-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6147"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06147-x","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The primary study received a waiver from the Dutch \u2018Medical Research Involving Human Subjects Act\u2019 from the medical ethical committee of Wageningen University and Research on December 20, 2020. Informed consent was obtained from each subject or, when applicable, from a legal representative, next of kin, or proxy in accordance to local protocols.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM reported receiving honoraria for advisory board meetings, lectures, and travel expenses from AOP pharma. PP reported receiving honoraria for advisory board meetings, lectures, research, and travel expenses from AOP Pharma, AM-Pharma, EBI, 4Teen4, and Adrenomed. AvZ reported receiving honoraria for advisory board meetings, lectures, research, and travel expenses from AOP Pharma, Abbott, Baxter, Cardinal Health, Danone-Nutricia, DIM3, Dutch Medical Food, Fresenius Kabi, GE Healthcare, InBody, Mermaid, Rousselot, and Lyric.","order":4,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"371"}}